Opendata, web and dolomites

FILODIAG

Ultra-Fast Molecular Filovirus Diagnostics - Sofia ref.: 115844

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FILODIAG project word cloud

Explore the words cloud of the FILODIAG project. It provides you a very rough idea of what is the project "FILODIAG" about.

guidance    magnetic    virus    limiting    instrument    withdrawal    diagnosis    gna    incoming    signs    urgent    resource    facilities    heated    gold    inmi    heating    decisive    sequence    ultra    accurately    sierra    genome    invasive    nurse    diagnostics    patients    immuno    centre    assay    tested    integrate    accurate    disease    standard    particles    turn    africa    crisis    12    overcoming    rely    emg    medical    infection    specificity    laser    reaction    diagnostic    ebd    competence    thoroughly    mub    binding    limited    west    ease    suspected    fever    copies    spread    laboratory    oligos    minutes    fluids    infected    dna    sensitivity    special    perform    care    nanoparticles    tests    clinical    leone    conventional    cooling    molecular    corresponding    stage    saliva    physicians    rapid    blood    biosafety    limit    evd    fast    usually    ebola    core    drastically    15    filodiag    tentative    there    time    risk    times    multiplexed    urine    rome    conduct    detecting    synthetic    preparation    lack    decisions    potentially    safely    point    italy    pcr   

Project "FILODIAG" data sheet

The following table provides information about the project.

Coordinator
GNA BIOSOLUTIONS GMBH 

Organization address
address: Am Klopferspitz 19
city: Martinsried
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.filodiag.eu
 Total cost 2˙260˙105 €
 EC max contribution 2˙260˙105 € (100%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2017-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GNA BIOSOLUTIONS GMBH DE (Martinsried) coordinator 1˙461˙750.00
2    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 404˙105.00
3    MENDELOVA UNIVERZITA V BRNE CZ (BRNO SEVER) participant 381˙750.00
4    EMERGENCY LIFE SUPPORT FOR CIVILIAN WAR VICTIMS ONG ONLUS IT (MILANO) participant 12˙500.00

Map

 Project objective

There is an urgent need for fast and accurate diagnostic tests in the current Ebola crisis. The rapid diagnosis of EVD during early and late stage of infection is a decisive step for risk assessment and for guidance to physicians to take the necessary decisions to limit the spread of the infection, and to safely nurse the infected patients. While fast and easy-to-use tests usually rely on immuno-diagnostic approaches, they typically lack high sensitivity and specificity. The gold standard for accurate diagnostics, (Real-Time) PCR, however, is limited in terms of processing time, high costs, and in most cases also in terms of ease of use and the need of special laboratory facilities.

The aim of this project is to provide an ultra-fast and accurate molecular diagnostic instrument that can perform a molecular Ebola test within 10-15 minutes. Patients, suspected of Ebola Virus Disease (EBD), due to fever and/or other clinical signs, could be rapidly and accurately tested at the Point-of-Care by withdrawal of blood, or less invasive fluids, such as saliva or urine.

The core technology of this proposal is based on laser-heated nanoparticles (Laser PCR), overcoming the time-limiting step of heating and cooling the reaction sample in conventional PCR allowing for drastically reduced turn-around times. The project partners (GNA, INMI, MUB, EMG) have the competence to integrate sample preparation with virus-binding magnetic particles, ultra-fast molecular diagnostics with Laser PCR, test the system in a biosafety level 4 laboratory in Rome, Italy, and thoroughly conduct field testing in a medical care centre in West Africa (Sierra Leone).

A tentative Ebola Laser PCR assay has already been set up, detecting 10 target copies of synthetic DNA oligos, corresponding to the Ebola genome sequence, in less than 12 minutes. The FILODIAG project will deliver a potentially multiplexed diagnostic system fast enough for point-of need testing of incoming patients at low-resource

 Deliverables

List of deliverables.
Final report Websites, patent fillings, videos etc. 2019-10-08 14:22:42
Patent application for nanomaghemite particles for virus model Websites, patent fillings, videos etc. 2019-05-30 17:11:07
Performance evaluation of each integration step of the test platform Documents, reports 2019-04-25 22:12:48
Patent application for nanomaghemite particles for Ebola Websites, patent fillings, videos etc. 2019-04-25 22:12:47
Providing one improved Pharos instrument Demonstrators, pilots, prototypes 2019-04-25 22:12:47
Higher process integration Websites, patent fillings, videos etc. 2019-04-25 22:12:47

Take a look to the deliverables list in detail:  detailed list of FILODIAG deliverables.

 Publications

year authors and title journal last update
List of publications.
2016 Rebuffo-Scheer et al.
Rapid detection of cDNA from Ebola virus isolate by Laser PCR
published pages: , ISSN: , DOI:
ECCMID 2016, Poster Presentation 3838 2019-05-15
2015 Krejcova et al.
Beads-based automatic pcr for detection of lentivirus with Ebola gp protein
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 48 2019-05-15
2015 Kizek et al.
Ebola gp protein fragments and their basic characterisati on provided by mass spectrometry, spectroscopy, chromatogra phy and electrochemi stry
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 45 2019-05-15
2015 Michalek P. et al.
The preparation and characterisation of lentivirus with Ebola gp protein
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 60 2019-05-15
2017 Rebuffo-Scheer et al.
Rapid One-Step RT-Laser PCR® detection of Ebola Virus: analytical performance evaluation and comparison with the commercially available RT-PCR kit RealStar® FilovirusScreen
published pages: , ISSN: , DOI:
ESCV 2017, poster presentation 2019-04-25
2017 INMI
TEST diagnostico per EBOLA: ricercatori INMI in missione in Sierra Leone
published pages: , ISSN: , DOI:
INMI Spallanzani Informa 2019-04-25
2018 INMI
Validazione di un nuovo test Diagnostico: “Ebola, ricercatori dello Spallanzani”
published pages: , ISSN: , DOI:
La Sanità del Lazio N°16, March 2018 2019-04-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FILODIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FILODIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More